166 related articles for article (PubMed ID: 8635869)
41. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.
Engert A; Gottstein C; Winkler U; Amlot P; Pileri S; Diehl V; Thorpe P
Leuk Lymphoma; 1994 May; 13(5-6):441-8. PubMed ID: 8069189
[TBL] [Abstract][Full Text] [Related]
42. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
[TBL] [Abstract][Full Text] [Related]
43. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
44. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma.
Ghetie MA; Podar EM; Gordon BE; Pantazis P; Uhr JW; Vitetta ES
Int J Cancer; 1996 Sep; 68(1):93-6. PubMed ID: 8895546
[TBL] [Abstract][Full Text] [Related]
45. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
46. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
47. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma.
Schnell R; Borchmann P; Staak JO; Schindler J; Ghetie V; Vitetta ES; Engert A
Ann Oncol; 2003 May; 14(5):729-36. PubMed ID: 12702527
[TBL] [Abstract][Full Text] [Related]
48. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
49. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.
Vallera DA; Burns LJ; Frankel AE; Sicheneder AR; Gunther R; Gajl-Peczalska K; Pennell CA; Kersey JH
J Immunol Methods; 1996 Oct; 197(1-2):69-83. PubMed ID: 8890895
[TBL] [Abstract][Full Text] [Related]
50. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
Stone MJ; Sausville EA; Fay JW; Headlee D; Collins RH; Figg WD; Stetler-Stevenson M; Jain V; Jaffe ES; Solomon D; Lush RM; Senderowicz A; Ghetie V; Schindler J; Uhr JW; Vitetta ES
Blood; 1996 Aug; 88(4):1188-97. PubMed ID: 8695836
[TBL] [Abstract][Full Text] [Related]
51. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest.
Ghetie MA; Picker LJ; Richardson JA; Tucker K; Uhr JW; Vitetta ES
Blood; 1994 Mar; 83(5):1329-36. PubMed ID: 7509655
[TBL] [Abstract][Full Text] [Related]
52. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
[TBL] [Abstract][Full Text] [Related]
53. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
54. Cytotoxicity of a novel anti-ICAM-1 immunotoxin on human myeloma cell lines.
Huang YW; Burrows FJ; Vitetta ES
Hybridoma; 1993 Dec; 12(6):661-75. PubMed ID: 7904588
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
Fishwild DM; Aberle S; Bernhard SL; Kung AH
Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice.
Morland BJ; Barley J; Boehm D; Flavell SU; Ghaleb N; Kohler JA; Okayama K; Wilkins B; Flavell DJ
Br J Cancer; 1994 Feb; 69(2):279-85. PubMed ID: 7507691
[TBL] [Abstract][Full Text] [Related]
57. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract][Full Text] [Related]
58. Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer.
Wawrzynczak EJ; Derbyshire EJ; Henry RV; Parnell GD; Smith A; Waibel R; Stahel RA
Br J Cancer Suppl; 1991 Jun; 14():71-3. PubMed ID: 1645577
[TBL] [Abstract][Full Text] [Related]
59. An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice.
Shapira S; Shapira A; Starr A; Kazanov D; Kraus S; Benhar I; Arber N
Gastroenterology; 2011 Mar; 140(3):935-46. PubMed ID: 21147107
[TBL] [Abstract][Full Text] [Related]
60. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.
Roy DC; Perreault C; Bélanger R; Gyger M; Le Houillier C; Blättler WA; Lambert JM; Ritz J
J Clin Immunol; 1995 Jan; 15(1):51-7. PubMed ID: 7539011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
